ASSESSMENT OF BLOOD GLUCOSE LEVELS, SERUM INSULIN, INFLAMMATORY MARKERS, AND METABOLIC PARAMETERS IN PREDICTING GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS.
Main Article Content
Keywords
Type 2 Diabetes Mellitus, Glycemic Control, Inflammatory Markers, CRP, IL-6, HOMA-IR, Serum Insulin, BMI, Triglycerides, HDL-C
Abstract
Background:
Type 2 Diabetes Mellitus (T2DM) is a growing global health concern characterized by chronic hyperglycemia due to insulin resistance and/or impaired insulin secretion. Inflammatory markers and metabolic parameters are increasingly recognized as important contributors to disease progression and glycemic control.
Objective:
To assess the relationship between blood glucose levels, serum insulin, inflammatory markers (CRP, IL-6), and metabolic parameters (BMI, lipid profile) in predicting glycemic control among patients with T2DM.
Methods:
This observational analytical study was conducted at the Department of Biochemistry and Department of General Medicine, Manipal College of Medical Sciences, Nepal. A total of 129 T2DM patients aged 30–65 years were included based on specific inclusion and exclusion criteria. Participants were categorized into good (HbA1c < 7%) and poor (HbA1c ≥ 7%) glycemic control groups. Biochemical and metabolic markers were measured and statistically compared between groups.
Results:
Patients with poor glycemic control had significantly higher levels of fasting blood glucose, postprandial glucose, serum insulin, HOMA-IR, CRP, IL-6, BMI, and triglycerides (p < 0.05). Conversely, HDL-C levels were significantly lower in this group. These findings indicate strong associations between poor glycemic control and increased insulin resistance, systemic inflammation, obesity, and dyslipidemia.
Conclusion:
Inflammatory and metabolic markers are significantly associated with poor glycemic control in T2DM patients. Monitoring these parameters may help in early detection of poor metabolic status and in guiding personalized treatment strategies to improve long-term diabetes outcomes.
References
2. Meriga RK et al. Correlation between glycemic control, lipid profile and C-reactive protein in adults with type 2 diabetes mellitus (Nellore, India). Int J Adv Med. 2020;7(9):1312–1317.
3. Gupta AK, Saxena R, Mahajan A, Bamniya S. Comparative analysis of serum insulin, insulin resistance, and inflammatory markers in type 2 diabetes mellitus patients and healthy controls. Int J Pharm Clin Res. 2025;17(1):323-7.
4. Pfützner A, Schöndorf T, Hanefeld M, Forst T. High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol. 2010 May 1;4(3):706-16.
5. American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20–S26.
6. Gupta AK, Saxena R, Mahajan A, Bamniya S. Comparative analysis of serum insulin, insulin resistance, and inflammatory markers in type 2 diabetes mellitus patients and healthy controls. Int J Pharm Clin Res. 2025;17(1):323-7.
7. Meriga RK, Shaik AP, Velaga MK. Correlation between glycemic control, lipid profile and C-reactive protein in adults with type 2 diabetes mellitus (Nellore, India). Int J Adv Med. 2020;7(9):1312–1317.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Jalari Ramu
Assistant Professor, Department of Biochemistry, Manipal College of Medical Sciences.